WeTrials
Recruiting

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor Tuvusertib (M1774)

What is this study?

This study is testing two new medications, peposertib and tuvusertib, combined together to fight advanced solid tumors. Researchers want to find the safest and most effective dose to help stop cancer cells from growing.

Who can participate?

Adults 18 and older with advanced solid tumors that have spread and no longer respond to standard treatments may be eligible. Participants must also have specific genetic markers in their tumors and a life expectancy of more than three months.

What will happen?

Participants will take the study medications and undergo regular health checks, including blood tests, tissue samples, and imaging scans like X-rays and MRIs to monitor their progress.

Where and when?

The study is currently recruiting patients and takes place at medical centers in locations such as Bethesda, Maryland, and Boston, Massachusetts.

Key Points
  • 1Tests a combination of two investigational cancer drugs.
  • 2Aims to find the safest dose for patients with advanced solid tumors.
  • 3Involves regular check-ups, scans, and lab tests to monitor your health.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.